Grace Therapeutics, Inc.

GRCESEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1444192

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	—	—	$100.0M	—	—
Cost of Goods and Services Sold	—	—	—	$76.0K	$76.0K
Research and Development Expense	$4.7M	$10.0M	$5.6M	$4.2M	$16.0M
Operating Income (Loss)	-$12.9M	-$52.2M	-$15.6M	-$16.4M	-$24.4M
Nonoperating Income (Expense)	-$1.8M	$184.0K	$5.1M	-$3.3M	-$1.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$14.7M	-$52.0M	-$10.5M	-$19.7M	-$25.5M
Income Tax Expense (Benefit)	-$1.8M	-$9.5M	-$648.0K	$0.00	—
Net Income (Loss) Attributable to Parent	-$12.9M	-$42.4M	-$9.8M	-$19.7M	-$25.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$73.3M	$79.1M	$128.6M	$62.5M	$22.9M
Assets, Current	$24.0M	$29.3M	$45.3M	$62.4M	$18.5M
Cash and Cash Equivalents, at Carrying Value	$23.0M	$27.9M	$30.3M	$50.9M	$14.2M
Accounts Receivable, after Allowance for Credit Loss, Current	—	$802.0K	$548.0K	$530.0K	$546.0K
Liabilities	$11.6M	$11.2M	$20.4M	$6.8M	$9.9M
Liabilities, Current	$1.7M	$3.4M	$3.3M	$1.6M	$7.4M
Stockholders' Equity Attributable to Parent	$68.0M	$108.3M	$55.7M	$13.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$12.3M	-$15.9M	-$17.2M	-$14.3M	-$23.0M
Net Cash Provided by (Used in) Investing Activities	$104.0K	$13.2M	-$3.5M	-$9.9M	$8.1M
Net Cash Provided by (Used in) Financing Activities	$7.4M	$304.0K	$0.00	$59.5M	$13.2M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)